摘要
目的:为调脂药的采购供应和临床合理使用提供参考。方法:对北京、成都、广州、杭州、上海、天津六地区74家医院2013年159 506例患者进行流行病学调查,统计并分析调脂药的销售金额、用药频度、日均费用(DDC)、实际日均剂量及排序比。结果:综合各地区,高脂血症患病率较高,为29.56%,呈地域性分布和年轻化趋势,伴有高血压、糖尿病及冠心病的患者患病率更高。阿托伐他汀使用量最大,但DDC也较高;相比之下,瑞舒伐他汀更具有市场优势;辛伐他汀DDC较低,更适用于经济受限患者。除北京、天津用药剂量较大外,其他地区多低于限定日剂量。结论:他汀类主导了调脂药市场,新型调脂药上市及联合用药为治疗提供了新选择。
OBJECTIVE：To provide reference for drug procurement and supply and rational use of lipid-regulating agents.METHODS：The epidemiological investigation was carried out among 159 506 cases from 74 hospitals in Beijing,Chengdu,Guangzhou,Hangzhou,Shanghai and Tianjin in 2013. The utilization of lipid-regulating agents was analyzed statistically in respects of purchase value,DDDs,DDC,actual average daily dose and sort ratio. RESULTS：The prevalence rate of hyperlipidemia was relatively high,accounting for 29.56% and showing a tendency of regional distribution and young age in all regions. The patients with hypertension,diabetes and coronary heart disease had a higher incidence to suffer from hyperlipidemia. The use of atorvastatin was in the first place,but it also had a higher DDC;while rosuvastatin hasd the advantage over aorvastatin in drug market.Simvastatin had a lower DDC and was more suitable for the patients with low income. The doses of lipid-regulating agents in other regions were lower than DDD except for those in Beijing and Tianjin. CONCLUSIONS：Statins dominate the lipid-regulating agents market. But new lipid-regulating agents and drug combination provide a new choice for clinical treatment.
出处
《中国药房》
CAS
北大核心
2015年第35期4908-4911,共4页
China Pharmacy
关键词
高脂血症
调脂药
流行病学调查
统计分析
北京
成都
广州
杭州
上海
天津
Hyperlipidemia
Lipid-regulating agents
Epidemiological investigation
Beijing
Chengdu
Guangzhou
Hangzhou
Shanghai
Tianjin
